Up And Up Allergy Relief

Up And Up Allergy Relief Manufacturers

• Target Corporation
  

  ×

  Up And Up Allergy Relief | Target Corporation

  

  ---

  adults and children 12 years of age and over

  take one 180 mg tablet with water once a day; do not take more than 1 tablet in 24 hours

  children under 12 years of age

  do not use

  adults 65 years of age and older

  ask a doctor

  consumers with kidney disease

  ask a doctor

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Target Corporation

  

  ---

  • use only with enclosed dosing cup

  adults and children 6 years and over

  1 teaspoonful (5 mL) or 2 teaspoonfuls (10 mL) once daily depending upon severity of symptoms; do not take more than 2 teaspoonfuls (10 mL) in 24 hours.

  adults 65 years and over

  1 teaspoonful (5 mL) once daily; do not take more than 1 teaspoonful (5 mL) in 24 hours.

  children 2 to under 6 years of age

  1/2 teaspoonful (2.5 mL) once daily. If needed, dose can be increased to a maximum of 1 teaspoonful (5 mL) once daily or 1/2 teaspoonful (2.5 mL) every 12 hours. Do not give more than 1 teaspoonful (5 mL) in 24 hours.

  children under 2 years of age

  ask a doctor

  consumers with liver or kidney disease

  ask a doctor

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Tris Pharma Inc

  

  ---

  Dosage should be individualized according to the needs and responses of the patient.

  Adults

  Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.

  Children (6 years and over)

  Methylphenidate hydrochloride oral solution should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.

  If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.

  Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.

  If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug.

  Methylphenidate hydrochloride oral solution should be periodically discontinued to assess the child's condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.

  Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Target Corporation

  

  ---

  • use only with enclosed dosing cup

  adults and children 6 years and over

  1 teaspoonful (5 mL) or 2 teaspoonfuls (10 mL) once daily depending upon severity of symptoms; do not take more than 2 teaspoonfuls (10 mL) in 24 hours.

  adults 65 years and over

  1 teaspoonful (5 mL) once daily; do not take more than 1 teaspoonful (5 mL) in 24 hours.

  children 2 to under 6 years of age

  1/2 teaspoonful (2.5 mL) once daily. If needed, dose can be increased to a maximum of 1 teaspoonful (5 mL) once daily or 1/2 teaspoonful (2.5 mL) every 12 hours. Do not give more than 1 teaspoonful (5 mL) in 24 hours.

  children under 2 years of age

  ask a doctor

  consumers with liver or kidney disease

  ask a doctor

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Target Corporation

  

  ---

  place 1 tablet on tongue; tablet disintegrates, with or without water adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Air Liquide Healthcare America Corporation

  

  ---

  There is currently no dosage information available for this product. We apologize for any inconvenience.

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Cardinal Health

  

  ---

  Gabapentin Capsules is given orally with or without food.

  If Gabapentin Capsules dose is reduced, discontinued or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).

  Postherpetic Neuralgia

  In adults with postherpetic neuralgia, Gabapentin Capsules therapy may be initiated as a single 300-mg dose on Day 1, 600 mg/day on Day 2 (divided BID), and 900 mg/day on Day 3 (divided TID). The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range. Additional benefit of using doses greater than 1800 mg/day was not demonstrated.

  Epilepsy

  Gabapentin Capsules is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.

  Patients >12 years of age: The effective dose of Gabapentin Capsules is 900 to 1800 mg/day and given in divided doses (three times a day) using 300 or 400 mg capsules. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules three times a day up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours.

  Pediatric Patients Age 3 to 12 years: The starting dose should range from 10 to 15 mg/kg/day in 3 divided doses, and the effective dose reached by upward titration over a period of approximately 3 days. The effective dose of Gabapentin Capsules in patients 5 years of age and older is 25 to 35 mg/kg/day and given in divided doses (three times a day). The effective dose in pediatric patients ages 3 and 4 years is 40 mg/kg/day and given in divided doses (three times a day) (see CLINICAL PHARMACOLOGY, Pediatrics.) Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours.

  It is not necessary to monitor gabapentin plasma concentrations to optimize Gabapentin Capsules therapy. Further, because there are no significant pharmacokinetic interactions among Gabapentin Capsules and other commonly used antiepileptic drugs, the addition of Gabapentin Capsules does not alter the plasma levels of these drugs appreciably.

  If Gabapentin Capsules is discontinued and/or an alternate anticonvulsant medication is added to the therapy, this should be done gradually over a minimum of 1 week.

  Dosage in Renal Impairment

  Creatinine clearance is difficult to measure in outpatients. In patients with stable renal function, creatinine clearance (CCr) can be reasonably well estimated using the equation of Cockcroft and Gault:

                 for females CCr=(0.85)(140-age)(weight)/[(72)(SCr)]
                 for males CCr=(140-age)(weight)/[(72)(SCr)]

  in which age is in years, weight is in kilograms and SCr is serum creatinine in mg/dL.

  Dosage adjustment in patients ≥ 12 years of age with compromised renal function or undergoing hemodialysis is recommended as follows (see dosing recommendations above for effective doses in each indication).

   Table 6. Gabapentin Capsules Dosage Based on Renal Function.    Renal Function
  Creatinine Clearance
  (mL/min)   Total Daily Dose
  Range
  (mg/day)   Dose Regimen
  (mg)

    ≥60

    900 to 3600

    300 TID

    400 TID

    600 TID

    800 TID

    1200 TID

    >30 to 59

    400 to 1400

    200 BID

    300 BID

    400 BID

    500 BID

    700 BID

    >15 to 29

    200 to 700

    200 QD

    300 QD

    400 QD

    500 QD

    700 QD

    15a

    100 to 300

    100 QD

    125 QD

    150 QD

    200 QD

    300 QD

    Post-Hemodialysis Supplemental Dose (mg)b

    Hemodialysis

    125b

    150b

    200b

    250b

    350b

    a For patients with creatinine clearance <15 mL/min, reduce daily dose in proportion to creatinine clearance (e.g., patients with a creatinine
  clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).

    b Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance as indicated in the upper portion
  of the table and a supplemental post-hemodialysis dose administered after each 4 hours of hemodialysis as indicated in the lower portion of the table.

  The use of Gabapentin Capsules in patients <12 years of age with compromised renal function has not been studied.

  Dosage in Elderly

  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Mayo Clinic

  

  ---

  Fludeoxyglucose F 18 Injection USP emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [see Description (11.2)].

  2.1 Recommended Dose for Adults

  Within the oncology, cardiology and neurology settings, the recommended dose for adults is 5 – 10 mCi (185 – 370 MBq) as an intravenous injection.

  2.2 Recommended Dose for Pediatric Patients

  Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection. The optimal dose adjustment on the basis of body size or weight has not been determined [see Use in Special Populations (8.4)].

  2.3 Patient Preparation To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study. Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour. Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [see Warnings and Precautions (5.2)].  Prior to Fludeoxyglucose F 18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 – 6 hours prior to the drug’s injection. In the cardiology setting, administration of glucose-containing food or liquids (e.g.,50 – 75 grams) prior to Fludeoxyglucose F 18 Injection USP facilitates localization of cardiac ischemia. 2.4 Radiation Dosimetry

  The estimated human absorbed radiation doses (rem/mCi) to a newborn (3.4 kg), 1-year old (9.8 kg), 5-year old (19 kg), 10-year old (32 kg), 15-year old (57 kg), and adult (70 kg) from intravenous administration of Fludeoxyglucose F 18 Injection USP are shown in Table 1. These estimates were calculated based on human2 data and using the data published by the International Commission on Radiological Protection4 for Fludeoxyglucose 18F. The dosimetry data show that there are slight variations in absorbed radiation dose for various organs in each of the age groups. These dissimilarities in absorbed radiation dose are due to developmental age variations (e.g., organ size, location, and overall metabolic rate for each age group). The identified critical organs (in descending order) across all age groups evaluated are the urinary bladder, heart, pancreas, spleen, and lungs.

  Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F 18 Injection USPa Organ  Newborn
  (3.4 kg)  1-year old
  (9.8 kg)  5-year old
  (19 kg)  10-year old
  (32 kg)  15-year old
  (57 kg)  Adult
  (70 kg) Bladder wallb  4.3  1.7  0.93  0.60  0.40  0.32 Heart wall  2.4  1.2  0.70  0.44  0.29  0.22 Pancreas  2.2  0.68  0.33  0.25  0.13  0.096 Spleen  2.2  0.84  0.46  0.29  0.19  0.14 Lungs  0.96  0.38  0.20  0.13  0.092  0.064 Kidneys  0.81  0.34  0.19  0.13  0.089  0.074 Ovaries  0.80  0.8  0.19  0.11  0.058  0.053 Uterus  0.79  0.35  0.19  0.12  0.076  0.062 LLI wall *  0.69  0.28  0.15  0.097  0.060  0.051 Liver  0.69  0.31  0.17  0.11  0.076  0.058 Gallbladder wall  0.69  0.26  0.14  0.093  0.059  0.049 Small intestine  0.68  0.29  0.15  0.096  0.060  0.047 ULI wall **  0.67  0.27  0.15  0.090  0.057  0.046 Stomach wall  0.65  0.27  0.14  0.089  0.057  0.047 Adrenals  0.65  0.28  0.15  0.095  0.061  0.048 Testes  0.64  0.27  0.14  0.085  0.052  0.041 Red marrow  0.62  0.26  0.14  0.089  0.057  0.047 Thymus  0.61  0.26  0.14  0.086  0.056  0.044 Thyroid  0.61  0.26  0.13  0.080  0.049  0.039 Muscle  0.58  0.25  0.13  0.078  0.049  0.039 Bone surface  0.57  0.24  0.12  0.079  0.052  0.041 Breast  0.54  0.22  0.11  0.068  0.043  0.034 Skin  0.49  0.20  0.10  0.060  0.037  0.030 Brain  0.29  0.13  0.09  0.078  0.072  0.070 Other tissues  0.59  0.25  0.13  0.083  0.052  0.042

  a MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al.1 and Jones et al.2
  b The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used.
  *LLI = lower large intestine; **ULI = upper large intestine

  2.5 Radiation Safety – Drug Handling Use waterproof gloves, effective radiation shielding, and appropriate safety measures when handling Fludeoxyglucose F 18 Injection USP to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel and other persons. Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [see Description (11.2)]. The dose of Fludeoxyglucose F 18 used in a given patient should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed. 2.6 Drug Preparation and Administration Calculate the necessary volume to administer based on calibration time and dose. Aseptically withdraw Fludeoxyglucose F 18 Injection USP from its container. Inspect Fludeoxyglucose F 18 Injection USP visually for particulate matter and discoloration before administration, whenever solution and container permit. Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. Use Fludeoxyglucose F 18 Injection USP within 12 hours from the EOS. 2.7 Imaging Guidelines Initiate imaging within 40 minutes following Fludeoxyglucose F 18 Injection USP administration. Acquire static emission images 30 – 100 minutes from the time of injection.

  Close
  No Recall

  More Info
• Target Corporation
  

  ×

  Up And Up Allergy Relief | Dolgencorp Inc

  

  ---

  • do not take more than directed (see overdose warning)

  adults and children 12 years and over

  • take 2 caplets at bedtime • do not take more than 2 caplets of this product in 24 hours

  children under 12 years

  do not use

  Close
  No Recall

  More Info